GlucoTrack, Inc. (GCTK)
| Market Cap | 2.41M -36.8% |
| Revenue (ttm) | n/a |
| Net Income | -16.89M |
| EPS | -17.13 |
| Shares Out | 3.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,446 |
| Open | 0.6430 |
| Previous Close | 0.6370 |
| Day's Range | 0.6377 - 0.6430 |
| 52-Week Range | 0.4311 - 15.9000 |
| Beta | 0.77 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About GCTK
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Financial Performance
Financial StatementsNews
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions
RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercializati...
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring ...
GlucoTrack Quarterly report: Q1 2026
GlucoTrack has published its Q1 2026 quarterly earnings report on May 14, 2026.
GlucoTrack Earnings release: Q1 2026
GlucoTrack released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
GlucoTrack submits IDE application to initiate study for CBGM technology
Glucotrack (GCTK) submitted its Investigational Device Exemption application to the U.S. Food and Drug Administration to initiate a US clinical study for its fully implantable continuous blood glucose...
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform Submission supports advancement of a long‑term, fully implantable, blood‑based con...
GlucoTrack Slides: Investor presentation
GlucoTrack has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
RUTHERFORD, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercializa...
GlucoTrack announces publication of peer-reviewed article on glucose sensors
Glucotrack (GCTK) announced the publication of a peer-reviewed scientific article in the Institute of Electrical and Electronics Engineers, IEEE, Sensors Journal characterizing the long-term in-vitro ...
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
RUTHERFORD, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercializa...
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026
GlucoTrack Earnings release: Q4 2025
GlucoTrack released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
GlucoTrack Annual report: Q4 2025
GlucoTrack has published its Q4 2025 annual report on March 30, 2026.
Why is Glucotrack Stock (GCTK) Up Nearly 30% Today?
Shares in diabetes-focused medical technology group Glucotrack ($GCTK) zoomed higher today after it said it was going to apply for a U.S. trial for its new glucose monitoring technology. FDA…
GlucoTrack to file IDE to FDA for continuous blood glucose monitoring technology
Glucotrack (GCTK) provided a recap of the critical operational milestones which have positioned the company to submit an IDE to the FDA for its continuous blood glucose monitoring technology, with…
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 Experience From Brazilian an...
GlucoTrack Transcript: EGM 2026
Three key proposals were presented: share issuances to an investor, warrant exercise approval, and auditor ratification. All proposals received the required stockholder approval, with final results to be filed with the SEC.
Glucotrack to Present at LSI USA '26 Medtech Innovation Summit
RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization...
GlucoTrack Proxy statement: Proxy Filing
GlucoTrack filed a proxy statement on February 9, 2026, providing details for shareholder voting and corporate governance matters.
GlucoTrack announces USPTO approval for issuance of patents for CBGM platform
Glucotrack (GCTK) announced that the US Patent and Trademark Office, USPTO, has issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258 for the Company’s continuous blood glucose monitoring...
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization ...
GlucoTrack Proxy statement: Proxy Filing
GlucoTrack filed a proxy statement on January 29, 2026, providing details for shareholder voting and corporate governance matters.
GlucoTrack files to sell 3.22M shares of common stock for holders
The company is not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by the selling stockholders.
GlucoTrack Registration statement: Registration Filing
GlucoTrack filed a registration statement on January 13, 2026, providing details about a securities offering with the SEC.
GlucoTrack prices 1.03M shares at $3.87 in private placement
Glucotrack (GCTK) entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,033,591 shares of common stock and warrants to purchase up to…